Median salary
$157,500
median over time
Typical range
$102.1k – $220k
25th–75th percentile
Disclosing pay
5.9%
325 of 5,516 roles
Live roles
5,516
open right now
Global Chief Medical Officer
Sr. Medical Director/Executive Director, Early Clinical Development
VP, Medical Affairs
Strategic Account Executive, Life Sciences
Strategic Client Partner, USA
Global Development Lead (GDL), Clinical Development
Executive Medical Director, Clinical Development
Executive Director, Global Medical Expert
| Company | Median | Roles |
|---|---|---|
Silvus Technologies
|
$170,000 | 40 |
Guild Garage Group
|
$101,250 | 26 |
Databricks
|
$258,900 | 21 |
ENSCO, Inc.
|
$102,076 | 19 |
Revolution Medicines
|
$274,500 | 18 |
| CP Compass Pathways | $205,000 | 12 |
Legend Biotech US
|
$340,497 | 7 |
BridgeBio Pharma
|
$230,000 | 7 |
| Location | Median | Roles |
|---|---|---|
| San Francisco | $258,900 | 36 |
| Seattle | $258,900 | 5 |
| Los Angeles | $170,000 | 26 |
| Boston | $157,500 | 3 |
| New York | $145,000 | 25 |
| Austin | $140,000 | 3 |
| Atlanta | $75,000 | 3 |
See every Drug Safety role
Browse the live listings, or save this search and get alerted the moment a new one posts.
The median salary for Drug Safety roles is $157,500 per year. Most pay falls between $102,076 (25th percentile) and $220,000 (75th percentile), with the broader 10th–90th percentile band running from $75,500 to $281,300.
These figures are computed live from 5,516 active Drug Safety roles on JobsRadar, of which 325 (5.9%) publish a salary range. Pay is normalized to annualized USD so roles can be compared on equal terms; the highest-paying roles listed above show their original posted currency. Numbers refresh every few hours as new roles are posted and older ones close.
Employers currently hiring well-paid Drug Safety roles include Legend Biotech US, Anthropic, Causaly and Revolution Medicines.
Salary transparency varies by employer and region, so the disclosing share above reflects only roles that publish pay — not every open position. Use it as a directional benchmark rather than an exact offer.